Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main Cytom X Therapeutics, Inc. Transaction History

Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main

$94.9 Billion
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2018 Aug 14, 2018	SELL	$21.38 - $29.68 $451,267 - $626,455	-21,107 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$21.76 - $34.22 $459,288 - $722,281	21,107 New	21,107 $600,000

Others Institutions Holding CTMX

# of Institutions

Shares Held

49.4M

Call Options Held

112K

Put Options Held

8.3K

Tang Capital Management LLC San Diego, CA

7.81M
Shares

$6.56 Million
0.79% of portfolio
Bvf Inc San Francisco, CA

5.23M
Shares

$4.39 Million
0.2% of portfolio
Vanguard Group Inc Valley Forge, PA

5.16M
Shares

$4.34 Million
0.0% of portfolio
Janus Henderson Group PLC London, X0

4.81M
Shares

$4.04 Million
0.0% of portfolio
Acadian Asset Management LLC Boston, MA

3.1M
Shares

$2.6 Million
0.01% of portfolio

View Full List

About CytomX Therapeutics, Inc.

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $55.4M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

More about CTMX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main, based on Form 13F filings with the SEC.

News

Stay updated on Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main with notifications on news.

Account